Dr Anthony Kong Academics Reader and Honorary Consultant Clinical Oncologist Contact details +44 (0) 20 7848 8302 anthony.kong@kcl.ac.uk
Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer Mumin, N. H., Drobnitzky, N., Patel, A., Lourenco, L. M., Cahill, F. F., Jiang, Y., Kong, A. & Ryan, A. J., 24 Jan 2019, In : BMC Cancer. 19, 1, 102. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1186/s12885-019-5295-z Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial Mehanna, H., Robinson, M., Hartley, A., Kong, A., Foran, B., Fulton-Lieuw, M., Dalby, M., Mistry, P. & Sen, M., 5 Jan 2019, In : Lancet. 393, 10166, p. 51-60 10 p. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1016/S0140-6736(18)32752-1 Evidence for the approach to the diagnostic evaluation of squamous cell carcinoma occult primary tumors of the head and neck Golusinski, P., Di Maio, P., Pehlivan, B., Colley, S., Nankivell, P., Kong, A., Hartley, A. & Mehanna, H., 30 Nov 2018, In : ORAL ONCOLOGY. 88, p. 145-152 8 p. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1016/j.oraloncology.2018.11.020 Should we de-escalate treatment for HPV positive oropharyngeal head and neck cancer? Mehanna, H., Bryant, J. & Kong, A., 24 Nov 2018, Critical Issues in Head and Neck Oncology. Vermorken, J., Budach, V., Leemans, C., Machiels, J-P., Nicolai, P. & O'Sullivan, B. (eds.). SPRINGER, p. 165-170 6 p. Research output: Chapter in Book/Report/Conference proceeding - Chapter. DOIs: https://doi.org/10.1007/978-3-319-98854-2 Circulating tumor DNA as a biomarker and liquid biopsy in head and neck squamous cell carcinoma Payne, K., Spruce, R., Beggs, A., Sharma, N., Kong, A., Martin, T., Parmar, S., Praveen, P., Nankivell, P. & Mehanna, H., 1 Jul 2018, In : Head and Neck. 40, 7, p. 1598-1604 7 p. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1002/hed.25140 Predictive biomarkers and EGFR inhibitors in squamous cell carcinoma of head and neck (SCCHN) Vigneswara, V. & Kong, A., Apr 2018, In : Annals of Oncology. 29, 4, p. 794-796 3 p. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.1093/annonc/mdy065 Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen Kong, A., Rea, D., Ahmed, S., Beck, J. T., López, R. L., Biganzoli, L., Armstrong, A. C., Aglietta, M., Alba, E., Campone, M., Schmitz, S-F. H., Lefebvre, C., Akimov, M. & Lee, S-C., 25 Apr 2016, In : Oncotarget. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.18632/oncotarget.8974 Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer Leung, W-Y., Roxanis, I., Sheldon, H., Buffa, F. M., Li, J., Harris, A. L. & Kong, A., 20 Mar 2015, In : Oncotarget. 6, 8, p. 5678-5694 Research output: Contribution to journal - Article. DOIs: https://doi.org/10.18632/oncotarget.3296 Profile of neratinib and its potential in the treatment of breast cancer Feldinger, K. & Kong, A., 2015, In : Breast Cancer. 2015, 7, p. 147-162 16 p. Research output: Contribution to journal - Article. DOIs: https://doi.org/10.2147/BCTT.S54414 ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer Feldinger, K., Generali, D., Kramer-Marek, G., Gijsen, M., Ng, T. B., Wong, J. H., Strina, C., Cappelletti, M., Andreis, D., Li, J-L., Bridges, E., Turley, H., Leek, R., Roxanis, I., Capala, J., Murphy, G., Harris, A. L. & Kong, A., 30 Aug 2014, In : Oncotarget. 5, 16, p. 6633-6646 Research output: Contribution to journal - Article. DOIs: https://doi.org/10.18632/oncotarget.1955 View all publications